Silverarc Capital Management LLC Sells 145,640 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Silverarc Capital Management LLC reduced its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 19.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 598,952 shares of the company's stock after selling 145,640 shares during the period. Centessa Pharmaceuticals accounts for about 2.2% of Silverarc Capital Management LLC's investment portfolio, making the stock its 14th largest holding. Silverarc Capital Management LLC owned about 0.45% of Centessa Pharmaceuticals worth $10,032,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Franklin Resources Inc. lifted its holdings in shares of Centessa Pharmaceuticals by 0.3% during the fourth quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company's stock valued at $38,668,000 after purchasing an additional 6,000 shares during the last quarter. Affinity Asset Advisors LLC boosted its holdings in Centessa Pharmaceuticals by 13.5% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,095,924 shares of the company's stock worth $18,357,000 after acquiring an additional 130,312 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Centessa Pharmaceuticals in the third quarter worth $4,305,000. Trexquant Investment LP increased its holdings in shares of Centessa Pharmaceuticals by 52.8% during the fourth quarter. Trexquant Investment LP now owns 261,184 shares of the company's stock valued at $4,375,000 after acquiring an additional 90,233 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Centessa Pharmaceuticals by 40.1% in the 4th quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company's stock worth $3,189,000 after purchasing an additional 54,482 shares during the last quarter. Institutional investors own 82.01% of the company's stock.

Analysts Set New Price Targets

CNTA has been the subject of a number of analyst reports. Piper Sandler started coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an "overweight" rating and a $38.00 price objective for the company. Guggenheim reiterated a "buy" rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. TD Cowen started coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating on the stock. Finally, Morgan Stanley reissued an "overweight" rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of "Buy" and an average price target of $27.71.

Centessa Pharmaceuticals Price Performance

CNTA stock traded up $0.18 during trading on Friday, hitting $13.79. 480,936 shares of the company's stock traded hands, compared to its average volume of 607,292. The business has a fifty day simple moving average of $14.42 and a 200 day simple moving average of $15.87. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -9.01 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.04. As a group, research analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Karen M. Anderson sold 6,471 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $16.86, for a total transaction of $109,101.06. Following the transaction, the insider now directly owns 54,322 shares in the company, valued at approximately $915,868.92. This represents a 10.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Saurabh Saha sold 14,656 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $12.29, for a total transaction of $180,122.24. Following the completion of the sale, the chief executive officer now directly owns 261,361 shares of the company's stock, valued at approximately $3,212,126.69. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 225,566 shares of company stock valued at $3,690,409 over the last three months. 11.59% of the stock is owned by company insiders.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.